Can Abilify Cause Sweaty Palms?
Yes, aripiprazole (Abilify) can cause sweaty palms (hyperhidrosis), though this is not a commonly emphasized side effect in the FDA labeling. The FDA label mentions body temperature regulation disruption as a class effect of antipsychotics 1, and case reports document aripiprazole-induced hyperhidrosis that resolved upon discontinuation 2.
Evidence for Hyperhidrosis
The FDA labeling for Abilify warns that antipsychotic agents can disrupt the body's ability to regulate core body temperature 1. While the label doesn't specifically list "sweaty palms" or "hyperhidrosis" among the most common adverse reactions (which include nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness), the thermoregulatory effects can manifest as excessive sweating.
Published case reports provide direct evidence: Two female patients developed hyperhidrosis with aripiprazole that completely resolved after discontinuation 2. The mechanism likely involves drug action at the hypothalamus, spinal thermoregulatory centers, sympathetic ganglia, or the eccrine-neuroeffector junction 2.
Clinical Management Approach
If a patient on aripiprazole develops sweaty palms:
- Confirm the temporal relationship between aripiprazole initiation/dose increase and symptom onset
- Rule out other causes of hyperhidrosis (hyperthyroidism, infection, other medications, anxiety)
- Consider dose reduction if clinically appropriate and symptoms are distressing
- Evaluate switching to an alternative antipsychotic if hyperhidrosis significantly impacts quality of life and adherence
- Monitor for other thermoregulatory issues, particularly in patients exercising strenuously, exposed to extreme heat, or taking anticholinergic medications 1
Important Caveats
While hyperhidrosis can be distressing and embarrassing, potentially leading to medication non-adherence 2, it is generally not a serious safety concern compared to other aripiprazole adverse effects like metabolic changes, tardive dyskinesia, or neuroleptic malignant syndrome 1.
The symptom should not be dismissed, as addressing it properly is essential for maintaining treatment adherence and patient quality of life 2.